Loading...
XHKG
2251
Market cap154mUSD
Dec 05, Last price  
11.66HKD
1D
-1.19%
1Q
-20.63%
IPO
-81.13%
Name

Beijing Airdoc Technology Co Ltd

Chart & Performance

D1W1MN
XHKG:2251 chart
P/E
P/S
6.99
EPS
Div Yield, %
Shrs. gr., 5y
-0.27%
Rev. gr., 5y
38.74%
Revenues
156m
-23.34%
30,415,00047,672,000115,181,000113,657,000203,964,000156,367,000
Net income
-255m
L+92.75%
-87,139,000-79,626,000-136,994,000-187,233,000-132,533,000-255,458,000
CFO
-165m
L
-58,696,000-42,856,000-112,093,000-380,443,00023,371,000-165,427,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Beijing Airdoc Technology Co., Ltd. provides AI-empowered retina-based early detection, diagnosis, and health risk assessment solutions for medical institutions and consumer healthcare providers in Mainland China and internationally. It offers Airdoc-AIFUNDUS (1.0), an AI-based software as a medical device for auxiliary diagnosis of diabetic retinopathy; Airdoc-AIFUNDUS (2.0) for the auxiliary diagnosis of hypertensive retinopathy, retinal vein occlusion, and age-related macular degeneration; and Airdoc-AIFUNDUS (3.0) for the auxiliary diagnosis of pathological myopia, retinal detachment, glaucoma detection, cataracts detection, ICVD/ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial, hypertension retinopathy, and anemia. The company also provides health risk assessment solutions to detect risk indicators, such as various lesions and diseases, hyperthyroidism, graves ophthalmopathy, retinal vein occlusion, dementia, Parkinson's disease, atrial fibrillation, and arteriosclerosis in a range of healthcare environments, including health checkup centers, community clinics, insurance companies, optometry centers, and pharmacies. In addition, it offers hardware devices, including fundus cameras. The company was incorporated in 2015 and is headquartered in Beijing, China.
IPO date
Nov 05, 2021
Employees
369
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT